Cellectis S.A. American Depositary Shares (CLLS)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-style investor, I start with what is proven. Cellectis is a clinical-stage gene-editing company; its value rests on BALLI-01, NatHaLi-01, and other candidates, not on current commerce. In fiscal Q2 2026, revenue was $5.2 million, net income was -$21.8 million, and the margin was -417.27%. The supplied revenue-growth figure is -68.74%, so the top line is shrinking, while trailing free cash flow was -$45.0 million, a FairStock-calculated FCF yield of -11.3%. That is heavy cash consumption for a $397.3 million market cap at the 2026-10-13 close of $1.10. The balance sheet carries a debt-to-equity ratio of 1.96; FairStock's Piotroski F-Score is 1/9 and Altman Z-Score is -0.59, both suggesting financial fragility. FairStock's return metrics are deeply negative: ROE -94.54% and ROCE -11.67%. At that close, FairStock's P/E is -1.72 and P/B is 1.96, so there is no earnings anchor—only asset and pipeline speculation. The FairStock Score is 23/100, and the computed Lynch category is none because there are only 0 years of filed results, needing 3. A moat is not visible in commercial terms; gene editing may have scientific promise, but no approved product means no pricing power, and a beta of 2.77 signals high volatility. The stock near its 52-week low of $1.09 may look cheap versus its range, but cheapness without earnings or cash flow is not value—it is a gamble on clinical success and future financing. I would need proof of durable revenue, controlled burn, and trial progress before calling it investment-grade.

In plain English: Cellectis is a clinical-stage biotechnology company that uses gene editing to develop cell therapies for cancer and other diseases. It is not yet profitable: in fiscal Q2 2026, revenue was $5.2 million and net loss was $21.8 million. With shrinking sales, negative cash flow, and no approved products, the share price looks speculative rather than clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer